Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025

Compass Therapeutics, Inc.

Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).
Cash and marketable securities $127M, down from $152M; cash runway into 2027.
Top-line data from COMPANION-002 (tovecimig in BTC) on track for end of Q1 2025.
Phase 2 trials for tovecimig in DLL4+ CRC and CTX-471 in NCAM+ tumors expected mid-2025.
CTX-10726 IND filing expected year-end 2025; CTX-8371 Phase 1 third cohort enrolled, no DLTs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.